Morgan Stanley Direct Lending Fund — Form 8-K Summary
Business context and reporting period
The Form 8-K reports events occurring on or after September 22, 2023. The registrant is a Delaware direct lending fund. The filing was signed September 27, 2023, and states that the related information was disclosed on September 28, 2023.
Material financing changes
- DLF Financing SPV LLC, a wholly owned subsidiary, entered into the Third Amendment to its BNP Funding Facility with BNP Paribas, U.S. Bank Trust Company, National Association, and participating lenders.
- The reinvestment period was extended to three years from the September 22, 2023 amendment date.
- Borrowing-base advance rates, concentration limits, eligibility criteria, lender-consent thresholds, revaluation-event thresholds, and other facility provisions were revised.
- An interest-coverage test was added.
- The applicable margin increased to 2.85% during the reinvestment period, from a prior range of 1.95% to 2.75%, and to 3.35% thereafter, from a prior range of 2.45% to 3.25%.
- The benchmark was changed from LIBOR to Term SOFR for U.S. dollar borrowings or adjusted cumulative compounded SONIA for pound sterling borrowings, with benchmark-replacement mechanics for CDOR.
- Other material terms of the BNP Funding Facility reportedly remain unchanged. The amendment creates or modifies a direct financial obligation of the registrant under Item 2.03.
Distributions and investment activity
| Item | Reported amount |
|---|---|
| Regular distribution | $0.50 per share |
| Supplemental distribution | $0.10 per share |
| Payment date | On or around October 25, 2023 |
| Record date | September 26, 2023 |
| New investment commitments, July 1–September 26, 2023 | Approximately $195.1 million |
| Portfolio company activity | 7 new and 12 existing portfolio companies |
| Investment mix | Approximately 99.3% first-lien debt and 0.7% other securities |
The regular distribution represented an annualized distribution yield of approximately 9.9%, and the supplemental distribution represented approximately 2.0%, calculated using the methodology described in the filing.
Financial metrics, outlook, and risks
The filing does not provide revenue, net income, net asset value, cash flow, margins, total debt, liquidity balances, or earnings guidance. It also does not provide management commentary or a quantified outlook. Key financing-related considerations include higher borrowing margins, revised advance rates and eligibility requirements, a new interest-coverage test, and updated concentration and revaluation thresholds.
Investor verification items
- Verify the facility’s amended borrowing capacity, advance rates, covenants, collateral requirements, and interest-coverage test in Exhibit 10.1 and its omitted schedules.
- Assess the effect of the higher borrowing margins on net investment income and distribution coverage.
- Confirm the actual payment of the $0.50 regular and $0.10 supplemental distributions and the basis for the stated annualized yields.
- Review portfolio-level exposure, concentration limits, and eligibility changes following the $195.1 million of new commitments.
- Confirm the transition mechanics and economic effects of Term SOFR, compounded SONIA, and CDOR benchmark replacement provisions.